MDMB-CHMINACA

MDMB-CHMINACA
Systematic (IUPAC) name
Methyl 2-{[1-(cyclohexylmethyl)-1H-indazole-3-carbonyl]amino}-3,3-dimethylbutanoate
Clinical data
Legal status
Identifiers
CAS Number 1185888-32-7
ChemSpider 32055574
Chemical data
Formula C22H31N3O3
Molar mass 385.5 g/mol

MDMB-CHMINACA (also known as MDMB(N)-CHM) is an indazole-based synthetic cannabinoid that is presumed to be a potent agonist of the CB1 receptor and has been sold online as a designer drug.[1][2][3][4] It is closely related to MDMB-FUBINACA, which caused at least 1000 hospitalizations and 40 deaths in Russia as consequence of intoxication.[5]

Legal status

MDMB-CHMINACA is listed in the Fifth Schedule of the Misuse of Drugs Act (MDA) and therefore illegal in Singapore as of May 2015.[6]

MDMB-CHMINACA is illegal in Switzerland as of December 2015.[7]

See also

References

  1. "MDMB-CHMINACA". Cayman Chemical. Retrieved 14 July 2015.
  2. Shevyrin V, Melkozerov V, Nevero A, Eltsov O, Shafran Y, Morzherin Y, Lebedev AT (Apr 2015). "Identification and analytical characteristics of synthetic cannabinoids with an indazole-3-carboxamide structure bearing a N-1-methoxycarbonylalkyl group". Analytical and Bioanalytical Chemistry 407: 6301–15. doi:10.1007/s00216-015-8612-7. PMID 25893797.
  3. Prof. SA Savchuk (2014). "Detection methods of psychoactive substances and liquid chromotograoghy detection of metabolites." (PDF). Russian Ministry of Health. Retrieved 14 July 2015.
  4. "Идентификация синтетических каннабимиметиков MDMB-CHMINACA, MDMB-FUBINACA и их метаболитов". CTS "SCIENCE". Retrieved 14 July 2015.
  5. "Очередная жертва спайса". Federal Drug Control Service of the Russian Federation. 17 March 2015. Retrieved 13 July 2015.
  6. "CNB NEWS RELEASE". Central Narcotics Bureau (CNB). 30 April 2015. Retrieved 14 July 2015.
  7. "Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien". Der Bundesrat.


This article is issued from Wikipedia - version of the Saturday, April 02, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.